Richard Snyder, Ph.D.

Vice President, Science & Technology, Pharma Services
Florida, USA

Key roles and responsibilities

  • Lead the science & technology team’s company wide initiative developing multi-generational manufacturing and analytical platforms used for the GMP production of viral vectors utilized for in vivo human gene therapies and ex vivo modified-cell based therapies

Professional highlights

  • Co-founder and Chief Scientific Officer of Brammer Bio, which was acquired by Thermo Fisher Scientific in 2019
  • Formerly an associate professor of molecular genetics and microbiology as well as director of biotherapeutic programs at the University of Florida, and assistant professor of pediatrics at Harvard Medical School
  • Experience in viral vector industry spans over thirty-three years; previously employed by Cell Cenesys, Somatix, Merlin, and Avigen
  • Engaged in the development of gene transfer vector and vaccine technology along with therapeutic applications
  • Author of over seventy scientific publications and also eight U.S. patents


  • Post-doctoral fellow at Johns Hopkins University School of Medicine
  • Doctor of Philosophy in microbiology from The State University of New York at Stony Brook
  • Bachelor’s degree in biology from Washington University in St. Louis

Scientific expertise

  • Virus biology
  • Viral vector development
  • cGMP viral vector manufacturing & analytical technologies
  • Viral vector mediated gene transfer
  • Development of novel viral vector-based human gene therapies

Related Sites

Additional Resources